Silence Therapeutics (NASDAQ:SLN) Posts Earnings Results, Misses Estimates By $0.14 EPS

Silence Therapeutics (NASDAQ:SLN) issued its quarterly earnings data on Thursday. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.14), Zacks reports. The company had revenue of $0.42 million for the quarter, compared to analyst estimates of $1.26 million. Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 95.93%.

Silence Therapeutics Stock Up 0.3%

Shares of SLN stock traded up $0.02 during mid-day trading on Friday, reaching $6.97. The stock had a trading volume of 326,786 shares, compared to its average volume of 422,206. The firm’s 50 day simple moving average is $6.41 and its 200 day simple moving average is $6.15. Silence Therapeutics has a one year low of $3.56 and a one year high of $8.40. The firm has a market cap of $329.19 million, a PE ratio of -4.38 and a beta of 1.52.

Institutional Trading of Silence Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC lifted its position in shares of Silence Therapeutics by 48.0% during the 4th quarter. Nantahala Capital Management LLC now owns 1,542,427 shares of the company’s stock worth $9,378,000 after buying an additional 500,000 shares during the period. Millennium Management LLC lifted its position in shares of Silence Therapeutics by 121.0% during the 4th quarter. Millennium Management LLC now owns 659,592 shares of the company’s stock worth $4,010,000 after buying an additional 361,080 shares during the period. Opaleye Management Inc. bought a new position in shares of Silence Therapeutics during the 4th quarter worth approximately $480,000. UBS Group AG lifted its position in shares of Silence Therapeutics by 34.5% during the 3rd quarter. UBS Group AG now owns 307,363 shares of the company’s stock worth $1,595,000 after buying an additional 78,854 shares during the period. Finally, Marshall Wace LLP lifted its position in shares of Silence Therapeutics by 87.1% during the 4th quarter. Marshall Wace LLP now owns 155,680 shares of the company’s stock worth $947,000 after buying an additional 72,461 shares during the period. Institutional investors own 98.73% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a report on Monday, March 2nd. HC Wainwright restated a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 13th. Jefferies Financial Group upgraded Silence Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $55.00.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.